3670-19-7

Basic information

• Product Name: 6-CHLOROTRYPTAMINE
• Synonyms: RARECHEM AH BS 0090;6-CHLOROTRYPTAMINE;3-(2-AMINOETHYL)-6-CHLOROINDOLE;6-CHLOROTRYPTAMINE free base;2-(6-chloro-1H-indol-3-yl)ethanamine;2-(6-chloro-1H-indol-3-yl)ethylamine;2-(6-chloro-1H-indol-3-yl)ethanamine hydrochloride
• CAS NO: 3670-19-7
• Molecular Formula: C₁₀H₁₁ClN₂
• Molecular Weight: 194.66
• Product Categories: Tryptamines
• Mol File: 3670-19-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 375.7°Cat760mmHg
• Flash Point: 181°C
• Appearance: /
• Density: 1.294g/cm³
• Vapor Pressure: 7.61E-06mmHg at 25°C
• Refractive Index: 1.675
• CAS DataBase Reference: 6-CHLOROTRYPTAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLOROTRYPTAMINE(3670-19-7)
• EPA Substance Registry System: 6-CHLOROTRYPTAMINE(3670-19-7)

Safety Data

• Hazardous Substances Data: 3670-19-7(Hazardous Substances Data)

Usage

Chemical compound

6-Chlorotryptamine

Also known as

6-CT

Classification

Tryptamine

Properties

Psychoactive

Potential

Antidepressant and anxiolytic agent

Mechanism of action

Acts as a partial agonist at the serotonin 5-HT1A receptor

Effects

Anxiolytic and antidepressant effects in animal models

Therapeutic potential

Treatment of mood disorders and anxiety

Investigated role

Modulating the effects of other psychoactive compounds, such as MDMA

InChI:InChI=1/C10H11ClN2/c11-8-1-2-9-7(3-4-12)6-13-10(9)5-8/h1-2,5-6,13H,3-4,12H2

Upstream product

• 61-54-1 tryptamine 
• 61220-58-4 2-(6-chloro-1H-indol-3-yl)acetonitrile 
• 33468-35-8 6-chloro-DL-tryptophan 
• 703-82-2 6-chloro-1H-indole-3-carbaldehyde 
• 878548-91-5 (E)-6-chloro-3-(2-nitroethenyl)-1H-indole 
• 151-56-4 ethyleneimine 
• 17422-33-2 6-chloroindole 
• 50517-12-9 1-(6-chloro-1H-indol-3-yl)-N,N-dimethylmethanamine 
• 151-50-8 potassium cyanide 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 25390-72-1 2-(6-chloro-1H-indol-3-yl)-N,N-dimethylethylamine 
• 1609064-15-4 N-[2-(6-chloro-1H-indol-3-yl)ethyl]-4-methylbenzenesulfonamide 

Relevant articles and documents

N-skatyltryptamines-dual 5-ht6r/d2r ligands with antipsychotic and procognitive potential

A series of N-skatyltryptamines was synthesized and their affinities for serotonin and dopamine receptors were determined. Compounds exhibited activity toward 5-HT1A, 5-HT2A, 5-HT6, and D2 receptors. Substitution patterns resulting in affinity/activity switches were identified and studied using homology modeling. Chosen hits were screened to determine their metabolism, permeability, hepatotoxicity, and CYP inhibition. Several D2 receptor antagonists with additional 5-HT6R antagonist and agonist properties were identified. The former combination resembled known antipsychotic agents, while the latter was particularly interesting due to the fact that it has not been studied before. Selective 5-HT6R antagonists have been shown previously to produce procognitive and promnesic effects in several rodent models. Administration of 5-HT6R agonists was more ambiguous-in naive animals, it did not alter memory or produce slight amnesic effects, while in rodent models of memory impairment, they ameliorated the condition just like antagonists. Using the identified hit compounds 15 and 18, we tried to sort out the difference between ligands exhibiting the D2R antagonist function combined with 5-HT6R agonism, and mixed D2/5-HT6R antagonists in murine models of psychosis.

Anti-cancer indole alkaloid compound, preparation method and application thereof

The invention relates to an anti-cancer compound, which is an indole alkaloid series compound and has a general formula (I). Indole alkaloids have a very good inhibitory effect on multiple solid tumors, such as human breast cancer cells, and further have an inhibitory effect on tumor growth. The compound has an inhibitory effect on the growth of cancer cells, but has no inhibitory effect on the growth of normal cells. The compound can be used alone or in combination with other drugs.

Indole derivative and uses thereof

The present invention relates to an indole derivative and uses thereof, wherein the compound and the pharmaceutical composition comprising the compound can be used for antagonizing orexin receptors. The present invention further relates to a method for preparing the compound and the pharmaceutical composition, and uses of the compound and the pharmaceutical composition in treatment or prevention of diseases associated with orexin receptors.